EXEL
Exelixis IncNasdaqResearch view
Healthcare · Biological Products, (No Diagnostic Substances) · Large-cap · SEC EDGAR FY 2026-01-02
Price history
Chart: TradingView’s own feed · page prices: 1D EOD🔒 Click to interact · scroll moves the page
Snapshot
SEC EDGAR · FY 2026-01-02SectorHealthcare
Market Cap$14.1B
Enterprise Value$13.8B
Income$782.6M
Sales$2.3B
Book/sh$8.72
Cash/sh$1.95
Dividend TTM—
Payout—
Employees—
IPO—
Quick Ratio3.50
Current Ratio3.56
Debt/Eq0.09
EPS (ttm)$2.78
EPS this Y58.0%
EPS past 3/5Y70.6%
Sales past 3/5Y12.9%
EPS Y/Y TTM58.0%
Sales Y/Y TTM7.0%
Shs Outstand247.78M
ROA27.5%
ROE36.2%
ROIC38.8%
Gross Margin—
Oper. Margin37.6%
Profit Margin33.7%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.
Revenue & Earnings — fiscal year
$1.4B
2021
$1.6B
2022
$1.8B
2023
$2.2B
2025
$2.3B
2026
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2021 | FY2022 | FY2023 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.6B | $1.8B | $2.2B | $2.3B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $286.7M | $201.5M | $170.9M | $604.6M | $872.2M |
| Net Income | $231.1M | $182.3M | $207.8M | $521.3M | $782.6M |
| Diluted EPS | $0.72 | $0.56 | $0.65 | $1.76 | $2.78 |
| Operating Cash Flow | $400.8M | $362.6M | $333.3M | $700.0M | $884.3M |
| Free Cash Flow | $346.6M | $334.9M | $292.9M | $671.5M | $875.8M |
Deep dive
Computed from the SEC EDGAR multi-year statementsOperating leverage — margins
GrossOperatingNet
FY26 cash-flow waterfall
Capital-light: capex is $8.4M against $884.3M operating cash
Follow the news. Track the move.
EXEL story timeline
Company updates and connected market context, with the dated price move attached.
1
Stories
0
Direct
COMMUNITY · $EXEL0 theses
POST YOUR TAKE →Related Stocks
Click to exploreSame Industry · Biological Products, (No Diagnostic Substances)
Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.